MDGL 213.38 Madrigal Pharmaceuticals, Inc.

⇒

Stock List ⇒ Madrigal Pharmaceuticals, Inc.

Range:	119.76-299.98	Vol Avg:	278351	Last Div:	0	Changes:	3.57
Beta:	-0.45	Cap:	4.65B	Currency:	USD	Exchange:	NASDAQ
Sector:	Healthcare			IPO:	Tue Feb 06 2007	Empoloyees:	376
CUSIP:	558868105	CIK:	0001157601	ISIN:	US5588681057	Country:	US
CEO:	Mr. William J. Sibold			Website:	https://www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Stock Details

MDGL 336

Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)

Yasmeen Rahimi·Wed May 29 2024

Piper Sandler

MDGL 390

Madrigal Pharmaceuticals (MDGL) PT Lowered to $390 at H.C. Wainwright

Ed Acre·Thu May 09 2024

H.C. Wainwright

MDGL 213.38 Madrigal Pharmaceuticals, Inc.

Stock Details

MDGL 336

MDGL 390

Про сайт

Новини маркету

Ринки

Найкращі для покупки